Why is Emcure Pharma falling/rising?

As of 28-Aug, Emcure Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 1,431.75, reflecting a decrease of 26.65 points or 1.83%. The stock has underperformed its sector by 0.99% today and has been on a downward trend for the last three days, resulting in a total decline of 4.16%. Despite having positive financial indicators such as a high return on capital employed (ROCE) of 20.99% and a low debt to EBITDA ratio of 0.53, the stock's long-term growth prospects appear poor, with operating profit growth averaging only 8.80% over the past five years. Additionally, a decrease in institutional investor participation, which has fallen by 0.81% in the last quarter, may be contributing to the stock's recent struggles.
In the broader market context, Emcure's short-term performance has been slightly better than the benchmark Sensex, with a 1-week return of -2.24% compared to the Sensex's -2.34%. However, over the past month, Emcure has outperformed the benchmark with a return of +2.34% against the Sensex's -1.00%. This indicates that while the stock is facing immediate challenges, it has shown some resilience in the longer term compared to the overall market. The combination of falling investor participation and concerns over valuation may be weighing on the stock, despite its recent positive quarterly results.